BLIS Technologies Ltd
BLT
Company Profile
Business description
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
Contact
399 Moray Place
Dunedin Central
DunedinOTA9016
NZLT: +64 34740988
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
34
Stocks News & Analysis
stocks
Wildly overvalued ASX stock is skating on thin ice
This company dominates its industry and could be flirting with regulatory intervention.
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.00 | 9.10 | -0.10% |
| CAC 40 | 7,709.32 | 74.29 | 0.97% |
| DAX 40 | 24,192.50 | 268.14 | 1.12% |
| Dow JONES (US) | 43,842.33 | 350.79 | -0.79% |
| FTSE 100 | 9,100.77 | 63.54 | -0.69% |
| HKSE | 25,081.63 | 171.00 | 0.69% |
| NASDAQ | 21,169.52 | 0.09 | 0.00% |
| Nikkei 225 | 41,059.15 | 264.29 | 0.65% |
| NZX 50 Index | 12,887.10 | 6.94 | 0.05% |
| S&P 500 | 6,324.46 | 20.60 | -0.32% |
| S&P/ASX 200 | 8,831.40 | 12.30 | -0.14% |
| SSE Composite Index | 3,639.67 | 5.67 | 0.16% |